Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000152.4(GAA):c.1051delG (p.Val351Cysfs)

Curation Version - 1.0
Curation History
JSON LD for Version 1.0

CA274024

188841 (ClinVar)

Gene: GAA

Condition: glycogen storage disease II

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: 5c8872e4-cd01-4359-8910-267bb59ac772

Approved on: 2020-05-03

Published on: 2020-05-26

HGVS expressions

NM_000152.4:c.1051delG

NM_000152.4(GAA):c.1051delG (p.Val351Cysfs)

NC_000017.11:g.80108385del

CM000679.2:g.80108385del

NC_000017.10:g.78082184del

CM000679.1:g.78082184del

NC_000017.9:g.75696779del

NG_009822.1:g.11830del

NM_000152.3:c.1051del

NM_001079803.1:c.1051del

NM_001079804.1:c.1051del

NM_000152.4:c.1051del

NM_001079803.2:c.1051del

NM_001079804.2:c.1051del

NM_000152.5:c.1051del

NM_001079803.3:c.1051del

NM_001079804.3:c.1051del

ENST00000302262.7:c.1051del

ENST00000390015.7:c.1051del

Pathogenic

PM2 PM3_Supporting PVS1 PP4

Evidence Links 5

Expert Panel

Lysosomal Diseases VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Lysosomal Diseases VCEP

This variant, c.1051delG (p.Val351Cysfs), is a frameshift variant which is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product, meeting PVS1. The variant is absent in gnomAD v 2.1.1, meeting PM2. This variant has been reported in three individuals with Pompe disease and residual GAA activating meeting PP4 specifications (PMIDs 20033296, 20817528, 22676651). Two of these individuals are compound heterozygous for the variant and c.-32-13T>G, phase unknown (PMIDs 20817528, 22676651). The other individual is compound heterozygous for the variant and c.1655T>C (p.Leu552Pro) (PMID 20033296). However, this in trans data will be used in the classification of p.Leu552Pro and is not included here in order to avoid a circular argument. Additional patients have been reported but were not included because the residual GAA activity was not provided and therefore PP4 cannot be assessed (PMID 24923245, 25455803). PM3_Supporting is met. There is a ClinVar entry for this variant (Variation ID 188841; 2 star review status) with one submitter classifying the variant as likely pathogenic and one a likely pathogenic. In summary, the variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3_Supporting, PP4.

PM2

This variant is absent in gnomAD v2.1.1.

PM3_Supporting

This variant has been reported in three individuals with Pompe disease and residual GAA activating meeting PP4 specifications (PMIDs 20033296, 20817528, 22676651). Two of these individuals are compound heterozygous for the variant and c.-32-13T>G, phase unknown (PMIDs 20817528, 22676651) (0.5 points). The other individual is compound heterozygous for the variant and c.1655T>C (p.Leu552Pro) (PMID 20033296), however, this in trans data will be used in the classification of p.Leu552Pro and is not included here in order to avoid a circular argument. Additional patients have been reported but were not included because the residual GAA activity was not provided and therefore PP4 cannot be assessed (PMID 24923245, 25455803). In total, 0.5 points were given for PM3, meeting PM3_Supporting.

This variant was found in 2 patients with c.-32-13T>G. c.-32-13T>G is a well known pathogenic variant. The phase of the variants was not confirmed. These patients do not meet PP4 criteria (control range for GAA activity was not provided). No points were awarded since in trans data for c.-32-13T>G has already been scored and the variants were not confirmed in trans. PubMed:24923245

This variant was found in patient 9 with c.-32-13T>G. c.-32-13T>G is a well known pathogenic variant. The phase of the variants was not confirmed and the patient does not meet PP4 criteria. Therefore, no points were awarded. PubMed:25455803

This variant was found in patient 2 with c.-32-13T>G. c.-32-13T>G is a well known pathogenic variant. The phase of the variants was not confirmed. This patient meets PP4 criteria. 0.5 points were awarded. PubMed:20817528

This variant was found in patient 4 with c.-32-13T>G. c.-32-13T>G is a well known pathogenic variant. The phase of the variants was not confirmed. This patient meets PP4 criteria. No points were awarded since in trans data for c.-32-13T>G has already been scored and the variants were not confirmed in trans. PubMed:22676651

PVS1

This is a frameshift variant which is predicted to result in a premature termination codon and nonsense mediated decay resulting in lack of gene product.

PP4

Three individuals have been reported with this variant and GAA activity <10% normal in lymphocytes, leukocytes or muscle samples, or <30% normal in cultured fibroblasts, or in the affected range in a clinically validated dried blood spot assay (PMIDs 20033296, 20817528, 22676651). This meets the specifications for PP4.

Patient 2 has GAA activity in the affected range when compared to the laboratory’s control range. In fibroblasts, GAA activity was 4.2 nmol/h/mg (normal range of 45–160 nmol/h/mg). PubMed:20817528

PubMed:20033296

Patient 4 has GAA activity in the affected range when compared to the laboratory’s control range. GAA activity measured in isolated lymphocytes with 4-methylumbelliferyl-α-D-glucopyranoside as substrate without acarbose was 0.01 nmole/mg/hr (normal range of 0.19-0.45 nmole/mg/hr) PubMed:22676651

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.